
Definitions of Suboptimal Response to DMT and Criteria for Switching Therapy




AAN, American Academy of Neurology.

1. Sormani MP et al. *Mult Scler*. 2013;19:605-612; 2. Sormani MP, De Stefano N. *Nat Rev Neurol*. 2013;9:504-512; 3. Giovannoni G et al. *Mult Scler*. 2017;23:1179-1187; 4. Kappos L et al. *Mult Scler*. 2016;22:1297-1305. 5. Rae-Grant A et al. *Neurology*. 2018;90:777-788.

Individualized Treatment Decisions: Therapy-Related Considerations






EFFICACY vs BURDEN of therapy^{1,2}

1. Soelberg Sorensen P. Acta Neurol Scand. 2017;136:168-186; 2. Ontaneda D et al. Lancet Neurol. 2019;18:973-980; 3. Freedman MS et al. Can J Neurol Sci. 2020;47:437-455.

Individualized Treatment Decisions: Patient-Related Considerations





Freedman MS et al. Can J Neurol Sci. 2020;47:437-455; Wingerchuk DM, Weinshenker BG. BMJ. 2016;354:i3518.